Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,815 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: matched control group Clear all

Conditions: Tolerance, Safety Issues, Aging
Interventions: Ketone ester, Non-ketone placebo; Other
Lead sponsor: Buck Institute for Research on Aging; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Novato, California

Conditions: Diabetic Retinopathy, Dyslipidemia
Interventions: 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy, Healthy Controls 15 age matched control subjects; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Adult Normals
Interventions: BMS-933043, Placebo matching with BMS-933043, Antacid Buffer Predose Solution; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder
Interventions: Stimulus-stimulus pairing, Vocal recorder; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 24 Months to 47 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cerebral Concussion, Brain Injuries
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 25 Years
Enrollment: 437 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: Exenatide, Exenatide matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more

Conditions: Heart Failure, Decompensated Heart Failure
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid-induced Constipation
Interventions: Placebo, Naldemedine; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 49
States / cities: Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more

Conditions: Pulmonary Hypertension
Interventions: Macitentan 10mg, Placebo sugar pill; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Depressive Disorder, Major
Interventions: Placebo, JNJ-42847922; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Anaheim, California • Chino, California • Lemon Grove, California + 24 more

Conditions: Drug Abuse
Interventions: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obsessive-Compulsive Disorder
Interventions: Bitopertin, Placebo, SSRI; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Disease
Interventions: Single Session Problem-Solving Intervention; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ulcerative Colitis
Interventions: PF-07054894, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Kissimmee, Florida • Tampa, Florida • Iowa City, Iowa + 1 more

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more

Conditions: Colorectal Cancer, Healthy Lifestyle, Behavior, Health, Health Behavior, Gastrointestinal Cancers
Interventions: RISE Personalized Self-Management Training (PSMT), Standardized Self-Management Training (SSMT); Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Postoperative Pain
Interventions: Ketamine, Placebo, Hydromorphone PCA; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: FCX-007 (dabocemagene autoficel; see below for FCX-007 description); Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 2 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2037
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more

Conditions: Anger, Suicidal Ideation
Interventions: Anger Reduction Treatment, Progressive Muscle Relaxation, Control Condition; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Alcohol Use Disorder, Posttraumatic Stress Disorder
Interventions: Mobile Mindfulness-Relapse Prevention (mMBRP), Exercise/healthy eating mobile app; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Menlo Park, California • San Francisco, California

Conditions: Pulmonary Arterial Hypertension
Interventions: rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Obesity, Insulin Resistance, Gonadal Dysfunction, Type 2 Diabetes
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Buck Institute Ketone Ester RCT

Dyslipidemia and Diabetic Retinopathy

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

Stimulus-Stimulus Pairing Study

The Effects of Head Trauma on Collegiate Athletes

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Monocyte Phenotypic Changes in Heart Failure

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Personalized Health Self-Management Training for Colorectal Cancer Survivors

Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Controlled Evaluation of a Computerized Anger-reduction Treatment for Suicide Prevention

Mobile Mindfulness for Alcohol Use and PTSD Among Veterans

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

The Health Influences of Puberty (HIP) Study